Abstract
The immune system is capable of recognizing and rejecting autologous tumor cells. This is suggested by reported cases of spontaneous remission of various cancers (1) and the presence of infiltrating leukocytes, the majority of which consist of T cells. However, the very existence of cancer and its inevitable progression without treatment demonstrates the inefficiency of the natural immune defense in combating tumors and the ability of neoplastic cells to evade immune-surveillance. Thus, the major objectives of immunotherapeutic approaches to the treatment of cancer rely on the ability to augment adaptive and natural immune responses against malignant cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krikorian, J., Portlock, C., Cooney, D., and Rosenberg, S. (1980) Spontaneous regression of non-Hodgkinās lymphoma. A report of nine cases. Cancer 46, 2093ā2099.
Lodge, P. A., Jones, L. A., Bader R. A., Murphy, G. P., and Salgaller, M. L. (2000) Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res. 60, 829ā833.
Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I., and Livington, P. O. (1998) Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4, 295ā302.
Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. (1996) Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29, 371ā380.
Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, H., Kenny, G. M., Troychak, M. J., et al. (1999) Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate 40, 125ā129.
Peshwa, M. V., Shi, J. D., Ruegg, C., Laus, R., and Schooten, W. C. (1998) Induction of prostate tumour-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostate acid phosphatase peptide. Prostate 36, 129ā138.
Heiser, A., Dahm, P., Yancey, D. R., Maurice, M. A., Boczkowski, D., Nair, S. K., et al. (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164, 5508ā5514.
Steinman, M. R. (1991) The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271ā296.
Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down regulated by tumour necrosis alpha. J. Exp. Med. 179, 1109ā1118.
Cella, M., Scheidegger, D., Plamer, L. K., Lane, P., Lanzavecchia, A., and Alber, G (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747ā752.
Rodriguez, A., Regnault A., Kleijmeer, M., Ricciardi-Castagnoli, P., and Amigorena, S. (1999) Selective transport of internalized antigens to the cytosol for the MHC class I presentation in dendritic cells. Nat. Cell. Biol. 1, 362ā368.
Bachmann, M. F., Lutz, M. B., Layton, G. T., Harris, S. J., Fehr, T., Rescigno, M., and Ricciardi-Castagnoli, P. (1996) Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur. J. Immunol. 26, 2595ā2600.
Inaba, K., Metlay, J. P., Crowley, M. T., and Steinman, R. M. (1990) Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172, 631ā640.
Shen, Z., Reznikoff, G., Dranoff, G., Kennteth, L., and Rock, L. (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723ā2730.
Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N. (2000) Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423ā433.
Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M-A., Ricciardi-Castagnoli, P., Rugarli, C., and Manfredi, A. A. (1998) Cutting edge: Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161, 4467ā4471.
Tsai, V., Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., et al. (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158, 1796ā1802.
Van Elsas, A., van der Burg, S. H., van der Minne, C. E., Borghi, M., Mourer, J. S., Melief, C. J. M., and Schrier, P. I. (1996) Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-Aā»0201-binding peptides from the Melan-A/Mart-1 self antigen. Eur. J. Immunol. 26, 1683ā1689.
Hsu, F., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, K., Taidi, B., et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nat. Med. 2, 52ā58.
Bender, A., Sapp, M., Schuler, G., Steinman, R. M., and Bhardwaj, N. (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Meth. 196, 121ā135.
Romani, N. and Reider, D (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Meth. 196, 137ā151.
Caux, C., Dezutter-Dambuyant, D., Schmitt, D., and Banchereau, J. (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360, 258ā261.
Thurnher, M., Papesh, C., Ramoner, R., Gastl, G., Bock, G., Radmayr, C., et al. (1997) In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp. Hematol. 25, 232ā237.
Pietschmann, P., Stockl, J., Draxler, S., Majdic, O., and Knapp, W. (2000) Functional and phenotypic characteristics of dendritic cells generated in human plasma supplemented medium. Scand. J. Immunol. 52, 377ā383.
Ali, S. A., Lynam, J., McLean, C. S., Entwisle, C., Loudon, P., Rojas, J. M., et al. (2002) Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) Herpes Simplex Virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage immunity. J. Immunol. 168, 3512ā3519.
Wang, L. R., Jeffery, F., Marty, G., Kuniyoshi, V., Bade, J., Ryback, E., et al. (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24, 66ā78.
Esche C., Shurin M. R., and Lotze MT. (1999) The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1, 72ā81.
Morse M. A. and Lyerly H. K. (2000) Clinical applications of dendritic cell vaccines. Curr. Opin. Mol. Ther. 2, 20ā28.
Aalamian, M., Pirtskhalaishvili, G., Nunez, A., Esche, C., Shurin, G. V., Huland, E., et al. (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46, 68ā75.
Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., and Tahara, H. (1999) Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59, 4035ā4041.
Melero, I., Duarte, M., Ruiz, J., Sangro, B., Galofre, J., Mazzolini, G., et al. (1999) Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 6, 1779ā1784.
Kikuchi, T. and Crystal, R. G. (1999) Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Human Gene Ther. 10, 1375ā1387.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc.
About this protocol
Cite this protocol
McArdle, S.E.B., Ali, S.A., Li, G., Mian, S., Rees, R.C. (2003). Phenotypic and Functional Differences of Dendritic Cells Generated Under Different In Vitro Conditions. In: Russell, P.J., Jackson, P., Kingsley, E.A. (eds) Prostate Cancer Methods and Protocols. Methods in Molecular Medicineā¢, vol 81. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-372-0:359
Download citation
DOI: https://doi.org/10.1385/1-59259-372-0:359
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-978-0
Online ISBN: 978-1-59259-372-9
eBook Packages: Springer Protocols